Vasee S Moorthy

Summary

Affiliation: Malaria Vaccine Initiative
Country: USA

Publications

  1. ncbi request reprint Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
    Samuel J McConkey
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Nat Med 9:729-35. 2003
  2. ncbi request reprint Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults
    Vasee S Moorthy
    Medical Research Council Laboratories, Banjul, The Gambia
    J Infect Dis 188:1239-44. 2003
  3. ncbi request reprint Malaria vaccine developments
    Vasee S Moorthy
    MRC Laboratories, Banjul, The Gambia
    Lancet 363:150-6. 2004
  4. pmc A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults
    Vasee S Moorthy
    Medical Research Council Laboratories, Banjul, Gambia
    PLoS Med 1:e33. 2004
  5. ncbi request reprint Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men
    Vasee S Moorthy
    Medical Research Council Laboratories, Banjul, Gambia
    J Infect Dis 189:2213-9. 2004
  6. ncbi request reprint Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria
    Sheila M Keating
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, Churchill Hospital, Oxford, United Kingdom
    J Immunol 175:5675-80. 2005
  7. ncbi request reprint Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
    Samuel J McConkey
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Nat Med 9:729-35. 2003
    ..Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans...
  2. ncbi request reprint Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults
    Vasee S Moorthy
    Medical Research Council Laboratories, Banjul, The Gambia
    J Infect Dis 188:1239-44. 2003
    ..Both CD4(+) and CD8(+) T cells were induced by these vaccines...
  3. ncbi request reprint Malaria vaccine developments
    Vasee S Moorthy
    MRC Laboratories, Banjul, The Gambia
    Lancet 363:150-6. 2004
    ..Although exact predictions are not possible, if sufficient funding were mobilised, a deployable, effective malaria vaccine is a realistic medium-term to long-term goal...
  4. pmc A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults
    Vasee S Moorthy
    Medical Research Council Laboratories, Banjul, Gambia
    PLoS Med 1:e33. 2004
    ....
  5. ncbi request reprint Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men
    Vasee S Moorthy
    Medical Research Council Laboratories, Banjul, Gambia
    J Infect Dis 189:2213-9. 2004
    ..These results highlight optimized combination regimens with general relevance to the development of vaccines targeting intracellular pathogens...
  6. ncbi request reprint Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria
    Sheila M Keating
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, Churchill Hospital, Oxford, United Kingdom
    J Immunol 175:5675-80. 2005
    ..This cultured assay identifies long-lasting protective T cell responses and therefore offers an attractive option for assessments of vaccine immunogenicity...
  7. ncbi request reprint Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006
    ..In this review we summarise the safety, immunogenicity and efficacy results from these malaria and tuberculosis vaccine clinical trials...